Stock Price
123.27
Daily Change
-1.55 -1.24%
Monthly
20.10%
Yearly
-59.33%
Q3 Forecast
122.44



Peers Price Chg Day Year Date
Avita Medical 1.40 -0.04 -2.44% -21.13% Jul/08
Ansell 31.78 -0.11 -0.34% 5.27% Jul/09
Cochlear 123.27 -1.55 -1.24% -59.33% Jul/09
CSL 123.71 -0.59 -0.47% -49.24% Jul/09
Fisher Paykel Healthcare 39.78 -0.02 -0.05% 9.89% Jul/09
Healius 0.39 0.01 1.30% -47.65% Jul/09
Integral Diagnostics 2.04 -0.01 -0.49% -21.54% Jul/09
Mesoblast 2.13 0.11 5.20% 29.18% Jul/09
Monash IVF 0.70 -0.01 -0.71% -6.04% Jul/09
Mayne Pharma 2.83 -0.03 -1.05% -45.58% Jul/09

Indexes Price Day Year Date
ASX200 8695 -90.10 -1.03% 1.23% Jul/09
ASX All Share 8923 -56.00 -0.62% 1.09% Jul/09
AU50 8530 -67.40 -0.78% 1.40% Jul/09

Cochlear traded at 123.27 this Thursday July 9th, decreasing 1.55 or 1.24 percent since the previous trading session. Looking back, over the last four weeks, Cochlear lost 20.10 percent. Over the last 12 months, its price fell by 59.33 percent. Looking ahead, we forecast Cochlear to be priced at 122.44 by the end of this quarter and at 115.17 in one year, according to Trading Economics global macro models projections and analysts expectations.

Cochlear Limited is an Australian-based company, which provides implantable hearing solutions. The Company designs and offers products and accessories for adults or children. The Company operates through three geographical segments: Americas, EMEA and Asia Pacific. Its products offer various ways to hear, such as automatically adjusting hearing to different environments and streaming sound from a smartphone. It provides various products, including Nucleus sound processors, Smart bimodal hearing solution, Nucleus implants, Nucleus implant reliability, Baha sound processors, Baha implants, Baha Softband, SoundArc. The Company’s accessories include True Wireless devices, Nucleus water-safe accessories, Keeping device in place.